Skip to main content
Premium Trial:

Request an Annual Quote

Oncology Pharma to Acquire Stake in Diagnomics

NEW YORK — Cancer drug developer Oncology Pharma said on Thursday that it has signed a letter of intent to acquire at least 50 percent of molecular genomics firm Diagnomics.

Diagnomics provides sequencing-based genomic testing services to industry and academic partners, and has developed an artificial intelligence-based drug development platform. The San Diego-based company also holds a minority stake in Korea-based Eone-Diagnomics Genome Center, a provider of clinical and consumer genetics products and services that it founded with Eone Life Science and that recently went public.

San Francisco-based Oncology Pharma said that Diagnomics' stake in the Eone-Diagnomics Genome Center is included in the planned acquisition. Additional terms of the letter of intent were not disclosed.

Diagnomics' "artificial intelligence combined with machine learning platform is a game changer because it is expected to significantly reduce drug development, clinical trial time, and cost," Oncology Pharma CEO Chuck Wagner said in a statement. "In addition, it is designed to accelerate the regulatory approval of drugs … [to] help make the drugs affordable, safer, and available sooner to the patients."

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.